454 related articles for article (PubMed ID: 22027535)
21. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design.
Hao J; Wang F; Wang X; Zhang D; Bi Y; Gao Y; Zhao X; Zhang Q
Eur J Pharm Sci; 2012 Sep; 47(2):497-505. PubMed ID: 22820033
[TBL] [Abstract][Full Text] [Related]
22. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
24. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery.
Jose S; Anju SS; Cinu TA; Aleykutty NA; Thomas S; Souto EB
Int J Pharm; 2014 Oct; 474(1-2):6-13. PubMed ID: 25102112
[TBL] [Abstract][Full Text] [Related]
25. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of hypericin-loaded solid lipid nanoparticles: physicochemical properties, photostability and phototoxicity.
Youssef T; Fadel M; Fahmy R; Kassab K
Pharm Dev Technol; 2012; 17(2):177-86. PubMed ID: 21047275
[TBL] [Abstract][Full Text] [Related]
27. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin.
Tian J; Pang X; Yu K; Liu L; Zhou J
Pharmazie; 2008 Aug; 63(8):593-7. PubMed ID: 18771008
[TBL] [Abstract][Full Text] [Related]
28. In vivo controlled release and prolonged antitumor effects of 2-methoxyestradiol solid lipid nanoparticles incorporated into a thermosensitive hydrogel.
Guo X; Xing Y; Zhang X; Li J; Mei Q; Zhang H; Chen C; Zhang Z; Cui F
Drug Deliv; 2012 May; 19(4):188-93. PubMed ID: 22643052
[TBL] [Abstract][Full Text] [Related]
29. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine.
Li Y; Dong L; Jia A; Chang X; Xue H
Int J Biol Macromol; 2006 May; 38(3-5):296-9. PubMed ID: 16600362
[TBL] [Abstract][Full Text] [Related]
30. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway.
Martins S; Costa-Lima S; Carneiro T; Cordeiro-da-Silva A; Souto EB; Ferreira DC
Int J Pharm; 2012 Jul; 430(1-2):216-27. PubMed ID: 22465548
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHX) based nanoparticles for targeted cancer therapy.
Kılıçay E; Demirbilek M; Türk M; Güven E; Hazer B; Denkbas EB
Eur J Pharm Sci; 2011 Oct; 44(3):310-20. PubMed ID: 21884788
[TBL] [Abstract][Full Text] [Related]
32. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol.
Teskac K; Kristl J
Int J Pharm; 2010 May; 390(1):61-9. PubMed ID: 19833178
[TBL] [Abstract][Full Text] [Related]
33. Design flexibility influencing the in vitro behavior of cationic SLN as a nonviral gene vector.
Vighi E; Montanari M; Hanuskova M; Iannuccelli V; Coppi G; Leo E
Int J Pharm; 2013 Jan; 440(2):161-9. PubMed ID: 22982257
[TBL] [Abstract][Full Text] [Related]
34. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
35. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
[TBL] [Abstract][Full Text] [Related]
36. Stability of lipid excipients in solid lipid nanoparticles.
Radomska-Soukharev A
Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
[TBL] [Abstract][Full Text] [Related]
37. Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles.
Akanda MH; Rai R; Slipper IJ; Chowdhry BZ; Lamprou D; Getti G; Douroumis D
Int J Pharm; 2015 Sep; 493(1-2):161-71. PubMed ID: 26200751
[TBL] [Abstract][Full Text] [Related]
38. Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting.
Swami R; Singh I; Jeengar MK; Naidu VG; Khan W; Sistla R
Int J Pharm; 2015; 486(1-2):287-96. PubMed ID: 25839415
[TBL] [Abstract][Full Text] [Related]
39. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells.
Zhang YL; Zhang ZH; Jiang TY; Ayman-Waddad ; Jing-Li ; Lv HX; Zhou JP
Pharmazie; 2013 Jan; 68(1):47-53. PubMed ID: 23444780
[TBL] [Abstract][Full Text] [Related]
40. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery.
Dong Z; Xie S; Zhu L; Wang Y; Wang X; Zhou W
Drug Deliv; 2011 Aug; 18(6):441-50. PubMed ID: 21554156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
